Scarica l'app Stockscreener
10.41
2.93%
0.52
Passage Bio Inc Borsa (PASG) Ultime notizie
Short Squeeze: What is the earnings history of Passage Bio IncTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PASG PE Ratio & Valuation, Is PASG Overvalued - Intellectia AI
Passage Bio (PASG) 2026 proxy details director elections, KPMG ratification and executive pay - Stock Titan
Passage Bio advances frontotemporal dementia trial and reports 2025 results - MSN
Stock List: Research Stocks from Around the World - GuruFocus
BOLD PE Ratio & Valuation, Is BOLD Overvalued - Intellectia AI
XCUR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026 - EIN News
Passage Bio Inc Stock: Gene Therapy Pioneer Faces Clinical and Funding Hurdles in Biotech Arena - AD HOC NEWS
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Bond Watch: Can Passage Bio Inc reach all time highs this year2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Oppenheimer Initiates Coverage on PASG with Outperform Rating | - GuruFocus
Oppenheimer Initiates Passage Bio at Outperform - Moomoo
Baird initiates Passage Bio stock coverage with outperform rating By Investing.com - Investing.com India
Baird initiates Passage Bio stock coverage with outperform rating - Investing.com
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
Oppenheimer initiates Passage Bio stock with outperform rating - Investing.com UK
Oppenheimer initiates Passage Bio stock with outperform rating By Investing.com - za.investing.com
Passage Bio, Inc. (NASDAQ:PASG) Receives $28.00 Average Price Target from Brokerages - Defense World
Passage Bio Inc Stock: Gene Therapy Innovator Focused on Rare Neurological Disorders Amid Biotech Vo - AD HOC NEWS
Passage Bio (PASG) price target increased by 21.85% to 40.39 - MSN
Options Flow: Can Sprout Social Inc sustain earnings growth2026 Institutional & Community Verified Watchlist Alerts - baoquankhu1.vn
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors - The Manila Times
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage BIO (PASG) CFO receives stock option grant for 15,610 shares - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
PASG Surges 13% on Thin Volume — But No Catalyst to Back It - Bitget
Buybacks Report: Can Passage Bio Inc stock outperform in a bear market2026 Setups & Reliable Breakout Forecasts - baoquankhu1.vn
Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding - AD HOC NEWS
Can Passage Bio Inc stock outperform in a bear market2026 Buyback Activity & Daily Entry Point Alerts - baoquankhu1.vn
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - The Globe and Mail
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results - MyChesCo
Weekly Trades: Is DISTW stock a hidden gemMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Lowered to Sell Rating by Wall Street Zen - Defense World
Will SBLK stock keep outperforming rivalsPortfolio Value Summary & AI Driven Price Forecasts - Naître et grandir
Portfolio Shifts: Does PRLD have declining or rising EPSTrade Signal Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trade Report: What insider trading reveals about Passage Bio Inc. stockPortfolio Profit Report & Precise Entry and Exit Recommendations - Naître et grandir
Passage Bio (PASG) Gets a Buy from Chardan Capital - The Globe and Mail
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Bitget
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):